{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:37:50Z","timestamp":1792553870712,"version":"4.5.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"7","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Stable, mixed-donor\u2013recipient chimerism after allogeneic hematopoietic stem cell transplantation (HSCT) for patients with sickle cell disease (SCD) is sufficient for phenotypic disease reversal, and results from differences in donor\/recipient\u2013red blood cell (RBC) survival. Understanding variability and predictors of RBC survival among patients with SCD before and after HSCT is critical for gene therapy research which seeks to generate sufficient corrected hemoglobin to reduce polymerization thereby overcoming the red cell pathology of SCD. This study used biotin labeling of RBCs to determine the lifespan of RBCs in patients with SCD compared with patients who have successfully undergone curative HSCT, participants with sickle cell trait (HbAS), and healthy (HbAA) donors. Twenty participants were included in the analysis (SCD pre-HSCT: N\u00a0= 6, SCD post-HSCT: N\u00a0= 5, HbAS: N\u00a0= 6, and HbAA: N\u00a0= 3). The average RBC lifespan was significantly shorter for participants with SCD pre-HSCT (64.1\u00a0days; range, 35-91) compared with those with SCD post-HSCT (113.4\u00a0days; range, 105-119), HbAS (126.0\u00a0days; range, 119-147), and HbAA (123.7\u00a0days; range, 91-147) (P&amp;lt;.001). RBC lifespan correlated with various hematologic parameters and strongly correlated with the average final fraction of sickled RBCs after deoxygenation (P&amp;lt;.001). No adverse events were attributable to the use of biotin and related procedures. Biotin labeling of RBCs is a safe and feasible methodology to evaluate RBC survival in patients with SCD before and after HSCT. Understanding differences in RBC survival may ultimately guide gene therapy protocols to determine hemoglobin composition required to reverse the SCD phenotype as it relates directly to RBC survival. This trial was registered at www.clinicaltrials.gov as #NCT04476277.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011397","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T18:28:04Z","timestamp":1704479284000},"page":"1806-1816","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation"],"prefix":"10.1182","volume":"8","author":[{"given":"Alexis K.","family":"Leonard","sequence":"first","affiliation":[{"name":"1Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD"},{"name":"2Department of Hematology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Furstenau","sequence":"additional","affiliation":[{"name":"1Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD"},{"name":"3Department of Pediatrics, Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0022-4138","authenticated-orcid":false,"given":"Zaina","family":"Inam","sequence":"additional","affiliation":[{"name":"1Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD"},{"name":"4Center for Cancer and Blood Disorders, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Luckett","sequence":"additional","affiliation":[{"name":"1Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Chu","sequence":"additional","affiliation":[{"name":"1Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6174-1609","authenticated-orcid":false,"given":"Selami","family":"Demirci","sequence":"additional","affiliation":[{"name":"1Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9556-5249","authenticated-orcid":false,"given":"Khaled","family":"Essawi","sequence":"additional","affiliation":[{"name":"5Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Gizan, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorg","family":"Gudmundsdottir","sequence":"additional","affiliation":[{"name":"1Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malikiya","family":"Hinds","sequence":"additional","affiliation":[{"name":"1Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"DiNicola","sequence":"additional","affiliation":[{"name":"1Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Li","sequence":"additional","affiliation":[{"name":"6Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9244-5407","authenticated-orcid":false,"given":"William A.","family":"Eaton","sequence":"additional","affiliation":[{"name":"6Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Cellmer","sequence":"additional","affiliation":[{"name":"6Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunde","family":"Wang","sequence":"additional","affiliation":[{"name":"7Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9835-6501","authenticated-orcid":false,"given":"Swee Lay","family":"Thein","sequence":"additional","affiliation":[{"name":"7Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Macari","sequence":"additional","affiliation":[{"name":"8bluebird bio, Inc, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"VanNest","sequence":"additional","affiliation":[{"name":"8bluebird bio, Inc, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M.","family":"Hsieh","sequence":"additional","affiliation":[{"name":"1Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Bonner","sequence":"additional","affiliation":[{"name":"8bluebird bio, Inc, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Pierciey","sequence":"additional","affiliation":[{"name":"8bluebird bio, Inc, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Tisdale","sequence":"additional","affiliation":[{"name":"1Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"issue":"6","key":"2024040915302476900_bib1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000208316","article-title":"Red cell life span in sickle cell trait","volume":"51","author":"Barbedo","year":"1974","journal-title":"Acta Haematol"},{"issue":"5","key":"2024040915302476900_bib2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1537-2995.2010.02926.x","article-title":"Red blood cell (RBC) survival determined in humans using RBCs labeled at multiple biotin densities","volume":"51","author":"Mock","year":"2011","journal-title":"Transfusion"},{"issue":"12","key":"2024040915302476900_bib3","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.24562","article-title":"Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia","volume":"91","author":"Quinn","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"2024040915302476900_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/03630260008993134","article-title":"Determinants of red cell survival and erythropoietic activity in patients with sickle cell anemia in the steady state","volume":"24","author":"Ballas","year":"2000","journal-title":"Hemoglobin"},{"issue":"12","key":"2024040915302476900_bib5","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI2484","article-title":"Time-dependent changes in the density and hemoglobin F content of biotin-labeled sickle cells","volume":"101","author":"Franco","year":"1998","journal-title":"J\u00a0Clin Invest"},{"issue":"17","key":"2024040915302476900_bib6","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2024040915302476900_bib7","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024040915302476900_bib8","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/ajh.24449","article-title":"Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease","volume":"91","author":"Altrock","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"2024040915302476900_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1537-2995.1999.39299154728.x","article-title":"Measurement of circulating red cell volume using biotin-labeled red cells: validation against 51Cr-labeled red cells","volume":"39","author":"Mock","year":"1999","journal-title":"Transfusion"},{"issue":"1","key":"2024040915302476900_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2002-11-3416","article-title":"Phosphatidylserine externalization in sickle red blood cells: associations with cell age, density, and hemoglobin F","volume":"102","author":"Yasin","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2024040915302476900_bib11","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1182\/blood.V96.10.3610","article-title":"The survival characteristics of dense sickle cells","volume":"96","author":"Franco","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2024040915302476900_bib12","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1182\/blood-2005-09-008318","article-title":"The effect of fetal hemoglobin on the survival characteristics of sickle cells","volume":"108","author":"Franco","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2024040915302476900_bib13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1537-2995.2004.03393.x","article-title":"Posttransfusion 24-hour recovery and subsequent survival of allogeneic red blood cells in the bloodstream of newborn infants","volume":"44","author":"Strauss","year":"2004","journal-title":"Transfusion"},{"issue":"5","key":"2024040915302476900_bib14","doi-asserted-by":"crossref","first-page":"E689","DOI":"10.1073\/pnas.1619054114","article-title":"Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"26","key":"2024040915302476900_bib15","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1073\/pnas.1922004117","article-title":"Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease","volume":"117","author":"Henry","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"49","key":"2024040915302476900_bib16","doi-asserted-by":"crossref","first-page":"11579","DOI":"10.1021\/acs.jpcb.8b07638","article-title":"Theoretical simulation of red cell sickling upon deoxygenation based on the physical chemistry of sickle hemoglobin fiber formation","volume":"122","author":"Dunkelberger","year":"2018","journal-title":"J\u00a0Phys Chem B"},{"issue":"40","key":"2024040915302476900_bib17","doi-asserted-by":"crossref","first-page":"e2210779119","DOI":"10.1073\/pnas.2210779119","article-title":"Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease","volume":"119","author":"Metaferia","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2024040915302476900_bib18","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood.V70.5.1245.1245","article-title":"Hemoglobin S gelation and sickle cell disease","volume":"70","author":"Eaton","year":"1987","journal-title":"Blood"},{"issue":"7","key":"2024040915302476900_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024040915302476900_bib20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.hoc.2022.03.008","article-title":"Gene therapy for hemoglobinopathies: beta-thalassemia, sickle cell disease","volume":"36","author":"Leonard","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"issue":"suppl 1","key":"2024040915302476900_bib21","first-page":"527","article-title":"Interim results from a phase 1\/2 clinical study of LentiGlobin gene therapy for severe sickle cell disease","volume":"130","author":"Kanter","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2024040915302476900_bib22","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1182\/blood.V128.22.1176.1176","article-title":"Interim results from a phase 1\/2 clinical study of LentiGlobin gene therapy for severe sickle cell disease","volume":"128","author":"Kanter","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2024040915302476900_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood-2021-147760","article-title":"Polyclonality strongly correlates with biological outcomes and is significantly increased following improvements to the phase 1\/2 HGB-206 protocol and manufacturing of LentiGlobin for sickle cell disease (SCD; bb1111) gene therapy (GT)","volume":"138","author":"Tisdale","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024040915302476900_bib24","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2021-152331","article-title":"Clinical results of the Drepaglobe Trial for sickle cell disease patients","volume":"138","author":"Magrin","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2024040915302476900_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024040915302476900_bib26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"2024040915302476900_bib27","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1182\/blood-2017-02-765891","article-title":"Treating sickle cell disease by targeting HbS polymerization","volume":"129","author":"Eaton","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2024040915302476900_bib28","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1182\/blood.V84.9.3182.3182","article-title":"Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on sickle cell disease","volume":"84","author":"Maier-Redelsperger","year":"1994","journal-title":"Blood"},{"issue":"4","key":"2024040915302476900_bib29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood-2013-09-528067","article-title":"Fetal hemoglobin in sickle cell anemia: a glass half full?","volume":"123","author":"Steinberg","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2024040915302476900_bib30","first-page":"1078","article-title":"Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea","volume":"89","author":"Steinberg","year":"1997","journal-title":"Multicenter Study of Hydroxyurea. Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/7\/1806\/2220815\/blooda_adv-2023-011397-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/7\/1806\/2220815\/blooda_adv-2023-011397-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T11:31:11Z","timestamp":1712662271000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/7\/1806\/506967\/In-vivo-measurement-of-RBC-survival-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011397","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]}}}